DBV TECHNOLOGIES |
Market Closed -
Other stock markets
|
After market 02:22:08 pm | |||
| 1.22 EUR | -1.61% |
|
1.219 | -0.08% |
| Sales 2024 * | 6.37M 6.94M | Sales 2025 * | 4.98M 5.42M | Capitalization | 119M 130M |
|---|---|---|---|---|---|
| Net income 2024 * | -125M -136M | Net income 2025 * | -118M -128M | EV / Sales 2024 * | -7.18 x |
| Net cash position 2024 * | 165M 180M | Net cash position 2025 * | 226M 246M | EV / Sales 2025 * | -21.4 x |
| P/E ratio 2024 * |
-1.8
x | P/E ratio 2025 * |
-3.25
x | Employees | 105 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 89.94% |
More Fundamentals
* Assessed data
More news
Latest transcript on DBV Technologies
More press releases
More news
| 1 day | +0.97% | ||
| 1 week | -3.69% | ||
| Current month | +0.64% | ||
| 1 month | +0.64% | ||
| 3 months | -8.81% | ||
| 6 months | -17.09% | ||
| Current year | -32.29% |
1 week
1.22
1.35
1 month
1.191.48
Current year
1.101.90
1 year
1.103.92
3 years
1.1010.90
5 years
1.1025.44
10 years
1.1086.64
| Managers | Title | Age | Since |
|---|---|---|---|
Daniel Tassé
CEO | Chief Executive Officer | 64 | 18-11-28 |
| Director of Finance/CFO | 54 | Nov. 05 | |
Pharis Mohideen
CTO | Chief Tech/Sci/R&D Officer | 59 | 19-07-21 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Timothy Morris
BRD | Director/Board Member | 61 | 21-02-28 |
Michel de Rosen
CHM | Chairman | 73 | 18-06-21 |
Don Soland
BRD | Director/Board Member | 65 | 15-03-05 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-28 | 1.22 | -1.61% | 77 807 |
| 24-05-27 | 1.24 | -0.64% | 59,990 |
| 24-05-24 | 1.248 | +0.65% | 68,382 |
| 24-05-23 | 1.24 | -2.67% | 135,000 |
| 24-05-22 | 1.274 | -2.00% | 83,014 |
Real-time Euronext Paris, May 28, 2024 at 08:08 am EDT
More quotes
DBV Technologies specializes in developing solutions for diagnosing and treating food allergies (primarily to peanuts and cow's milk) using a patch (Viaskin®) that administers active ingredients into the top layers of the skin.
Sector
Pharmaceuticals
Calendar
2024-07-28
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
1.24
EUR
Average target price
4.733
EUR
Spread / Average Target
+281.72%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -32.29% | 129M | |
| +15.93% | 79.03B | |
| +8.65% | 8.78B | |
| -16.73% | 4.83B | |
| +48.34% | 4.65B | |
| +2.03% | 3.89B | |
| +17.97% | 2.34B | |
| -26.94% | 2.18B | |
| +16.55% | 2.11B | |
| -36.25% | 2B |
- Stock Market
- Equities
- DBV Stock
